Regeneron ends REGN7041 uveitis study on safety영어 원문
Phase 1/2 trial for non-infectious uveitis terminated after unfavorable benefit-risk review, hitting pipeline
첫날 +0.5% · 5일 후 +2.9%
실적호재
Regeneron Q2 Beat, Dupixent & Eylea HD Drive Growth영어 원문
Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
첫날 +6.2% · 5일 후 +4.6%
›전개 과정 4회
2026-07-30Q2 results beat on revenue and profit, driven by strong demand for Dupixent and high-dose Eylea.
2026-07-30Q2 revenue $4.3B beat; Dupixent global sales +38%, Eylea HD US sales +52%
2026-08-05Citigroup raises PT to $740 post-earnings, reflecting institutional confidence
2026-08-06Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
규제악재
Multiple Law Firms Announce Securities Class Action Lawsuits Against Regeneron영어 원문
Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
첫날 -0.7% · 5일 후 -0.7%
›전개 과정 18회
2026-07-18At least four independent law firms have announced investigations or lawsuits alleging securities fraud, inviting investors to join.
2026-07-18Multiple law firms issue reminders, including DJS, Schall, and Faruqi, with deadline on Sept 14, 2026.
2026-07-20Two additional law firms (DJS Law Group, Schall Law Firm) issued reminders today, same line as prior event, no new facts.
2026-07-20On July 20, 2026, multiple law firms including Bernstein Liebhard, DJS Law Group, Faruqi & Faruqi, Schall Law Firm, and Levi & Korsinsky issued investor alerts regarding a securities class action lawsuit against Regeneron for alleged securities law violations, with a lead plaintiff deadline set for September 14, 2026.
2026-07-22Multiple firms confirm class action with Sept 14 deadline, allegations involve Fianlimab-Libtayo trial disclosures.
2026-07-23Multiple law firms issue class action notices, adding Sept 14 lead plaintiff deadline and Phase 3 trial disclosure allegations
2026-07-24Multiple law firms issue reminders with Sept 14 deadline, no new facts, just repetition.
2026-07-24Multiple law firms issued notices today alleging trial misrepresentations, with September 14 deadline highlighted
2026-07-27BFA, Bronstein, Faruqi among firms flagging Sept 14 lead plaintiff deadline after 9% stock drop triggered fraud suit
2026-07-28Multiple law firms issue class action reminders, alleging misleading statements on Fianlimab-L Phase III trial; stock fell nearly 10%
2026-07-29Multiple law firms issue reminders over class action alleging statements on Fianlimab-Libtayo trial, deadline Sept 14.
2026-07-31BFA, Bronstein, Pomerantz remind investors of class action deadlines
2026-08-01Multiple law firms issued reminders today, revealing details of key trial failure, escalating the litigation.
2026-08-01BofA's stake increase coincides with lawsuit deadline, ongoing litigation risk
2026-08-04Multiple law firms file class actions over trial disclosures, stock drops nearly 10%
2026-08-04Multiple firms issued reminders today; lawsuit relates to Fianlimab-L trial failure and stock drop, deadline Sept 14.
2026-08-05Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
애널리스트
Analysts Raise Regeneron PT & Upgrade영어 원문
Citi raises PT to $740 (Neutral); Wall Street Zen upgrades to Buy; reflects cautious optimism on Eylea HD & pipeline
첫날 +1.0% · 5일 후 +3.8%
제품악재
Biocon Launches Eylea Biosimilar Yesafili in the US영어 원문
Biocon announces US launch of Yesafili, competing with Regeneron's Eylea
첫날 -0.4% · 5일 후 +6.4%
제품악재
Biocon Launches Yesafili, a Biosimilar to Regeneron's Eylea 2 mg영어 원문
Biocon commercially launches Yesafili in the U.S., directly competing with Regeneron's Eylea for ophthalmology conditions
Regeneron ends REGN7041 uveitis study on safety영어 원문
Phase 1/2 trial for non-infectious uveitis terminated after unfavorable benefit-risk review, hitting pipeline
첫날 +0.5% · 5일 후 +2.9%
실적호재
Regeneron Q2 Beat, Dupixent & Eylea HD Drive Growth영어 원문
Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
첫날 +6.2% · 5일 후 +4.6%
›전개 과정 4회
2026-07-30Q2 results beat on revenue and profit, driven by strong demand for Dupixent and high-dose Eylea.
2026-07-30Q2 revenue $4.3B beat; Dupixent global sales +38%, Eylea HD US sales +52%
2026-08-05Citigroup raises PT to $740 post-earnings, reflecting institutional confidence
2026-08-06Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
규제악재
Multiple Law Firms Announce Securities Class Action Lawsuits Against Regeneron영어 원문
Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
첫날 -0.7% · 5일 후 -0.7%
›전개 과정 18회
2026-07-18At least four independent law firms have announced investigations or lawsuits alleging securities fraud, inviting investors to join.
2026-07-18Multiple law firms issue reminders, including DJS, Schall, and Faruqi, with deadline on Sept 14, 2026.
2026-07-20Two additional law firms (DJS Law Group, Schall Law Firm) issued reminders today, same line as prior event, no new facts.
2026-07-20On July 20, 2026, multiple law firms including Bernstein Liebhard, DJS Law Group, Faruqi & Faruqi, Schall Law Firm, and Levi & Korsinsky issued investor alerts regarding a securities class action lawsuit against Regeneron for alleged securities law violations, with a lead plaintiff deadline set for September 14, 2026.
2026-07-22Multiple firms confirm class action with Sept 14 deadline, allegations involve Fianlimab-Libtayo trial disclosures.
2026-07-23Multiple law firms issue class action notices, adding Sept 14 lead plaintiff deadline and Phase 3 trial disclosure allegations
2026-07-24Multiple law firms issue reminders with Sept 14 deadline, no new facts, just repetition.
2026-07-24Multiple law firms issued notices today alleging trial misrepresentations, with September 14 deadline highlighted
2026-07-27BFA, Bronstein, Faruqi among firms flagging Sept 14 lead plaintiff deadline after 9% stock drop triggered fraud suit
2026-07-28Multiple law firms issue class action reminders, alleging misleading statements on Fianlimab-L Phase III trial; stock fell nearly 10%
2026-07-29Multiple law firms issue reminders over class action alleging statements on Fianlimab-Libtayo trial, deadline Sept 14.
2026-07-31BFA, Bronstein, Pomerantz remind investors of class action deadlines
2026-08-01Multiple law firms issued reminders today, revealing details of key trial failure, escalating the litigation.
2026-08-01BofA's stake increase coincides with lawsuit deadline, ongoing litigation risk
2026-08-04Multiple law firms file class actions over trial disclosures, stock drops nearly 10%
2026-08-04Multiple firms issued reminders today; lawsuit relates to Fianlimab-L trial failure and stock drop, deadline Sept 14.
2026-08-05Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
애널리스트
Analysts Raise Regeneron PT & Upgrade영어 원문
Citi raises PT to $740 (Neutral); Wall Street Zen upgrades to Buy; reflects cautious optimism on Eylea HD & pipeline
첫날 +1.0% · 5일 후 +3.8%
제품악재
Biocon Launches Eylea Biosimilar Yesafili in the US영어 원문
Biocon announces US launch of Yesafili, competing with Regeneron's Eylea
첫날 -0.4% · 5일 후 +6.4%
제품악재
Biocon Launches Yesafili, a Biosimilar to Regeneron's Eylea 2 mg영어 원문
Biocon commercially launches Yesafili in the U.S., directly competing with Regeneron's Eylea for ophthalmology conditions
